About the Authors
- Lara J. Wolfson
-
* E-mail: LWolfson@its.jnj.com
Affiliation Janssen Pharmaceutica NV, Beerse, Belgium
- Anna Walker
-
Affiliation HERON Commercialization, London, United Kingdom
- Robert Hettle
-
Affiliation HERON Commercialization, London, United Kingdom
- Xiaoyan Lu
-
Affiliation Janssen Pharmaceutica NV, Beerse, Belgium
- Chrispin Kambili
-
Affiliation Janssen Global Services LLC, Raritan, New Jersey, United States of America
- Andrew Murungi
-
Affiliation Janssen (Janssen-Cilag), High Wycombe, United Kingdom
- Gerhart Knerer
-
Affiliation Janssen (Janssen-Cilag), High Wycombe, United Kingdom
Competing Interests
The authors have the following interests: L.J. Wolfson and X. Lu were employed by Janssen Pharmaceutica N.V. at the time of writing this manuscript; C. Kambili was employed by Janssen Global Services LLC; and G. Knerer and A. Murungi were employed by Janssen-Cilag. R. Hettle and A. Walker were commissioned by Janssen Pharmaceutica N.V. to prepare the cost-effectiveness model that this manuscript is based on. Anna Walker and Robert Hettle are employed by HERON™ Commercialization. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: LW AW RH. Performed the experiments: LW AW RH XL. Analyzed the data: LW AW RH CK GK AM. Wrote the paper: LW AW RH CK GK AM. Acquisition of data: LW AW RH XL. Providing critical revision of the manuscript: LW AW RH CK GK AM. Providing final approval of the version to publish: LW AW RH CK GK AM.